For nearly 20 years, Masimo (NASDAQ: MASI) has been focused on a singular mission—to make noninvasive patient monitoring technologies that are more effective and reliable, and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and new applications. The result is a portfolio of clinically proven products that lead the way in innovation, performance and patient safety.

Masimo SET Pulse Oximetry has been demonstrated clinically superior in more than 100 independent and objective studies. These objective, peer-reviewed studies demonstrate Masimo’s revolutionary Signal Extraction Technology outperforms other pulse oximeters in the marketplace. Many of the world’s top hospitals have made Masimo SET their primary pulse oximetry platform, including four out of the top five hospitals in the United States as listed on the US News and World Report Honor Roll and leading patient monitoring companies around the world have adopted Masimo SET. In addition to a complete array of Masimo-branded monitors, Masimo is integrated into more than 90 multiparameter monitors and 40 monitoring brands.

From our invention of Signal Extraction Technology and the introduction of Read-Through Motion and Low Perfusion pulse oximetry, to our most recent launch of Masimo Rainbow SET Pulse CO-Oximetry capable of monitoring carboxyhemoglobin and methemoglobin continuously and noninvasively, we are committed to providing clinicians with tools to make precise and timely diagnoses that lead to better treatment decisions. We invite you to learn more about the products, people, and services that have brought us to where we are today.